## MEETING AGENDA

## Friday, December 8

8:00 a.m. **MEETING RECONVENES** 

8:15-12:00 a.m. **Discussion of Broader Use of DES and its Implications,** 

continued

8:15-9:40 a.m. **Open Public Hearing Session** 

Public attendees who have contacted the Executive Secretary prior to the meeting will address the Committee and present information relevant to the agenda. Speakers are asked whether or not they have any financial involvement

with the product or competing products being discussed.

Panel Q&A

9:40-11:00 a.m. **Open Public Hearing Session** 

Public attendees who have contacted the Executive Secretary prior to the meeting will address the Committee and present information relevant to the agenda. Speakers are asked whether or not they have any financial involvement

with the product or competing products being discussed.

11:00-11:15 a.m. **BREAK** 

11:15-11:35 a.m. **Panel Q&A** 

11:25-12:30 p.m. **Open Public Hearing Session** 

Public attendees who have contacted the Executive Secretary prior to the meeting will address the Committee and present information relevant to the agenda. Speakers are asked whether or not they have any financial involvement

with the product or competing products being discussed.

Panel Q&A

12:30-1:30 p.m. **LUNCH BREAK** 

1:30-4:30 p.m. **Discussion of Broader Use of DES and its Implications,** 

continued

Open Public Hearing Session

Public attendees who have contacted the Executive Secretary prior to the meeting will address the Committee and present information relevant to the agenda. Speakers are asked whether or not they have any financial involvement with the product or competing products

being discussed.

Open Public Hearing Session - Unscheduled speakers

## **MEETING AGENDA (continued)**

 $2:50\hbox{-}4:30~p.m. \hspace{1.5cm} \textbf{FDA Questions to the Panel (includes 15 min break at} \\$ 

discretion of the Chair)

4:30 p.m. **MEETING ADJOURNED**